MedTrace Logo

Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil

NCT00939198 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2018-08-01

Study results available
· View outcomes & findings →

Summary

Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset of volunteers. The clinical trial component of this study involves skin testing for immediate-type hypersensitivity to the Na-ASP-2 Antigen. Both prick-puncture and intradermal tests will be applied.

Conditions

  • Hookworm Infection

Interventions

BIOLOGICAL

Na-ASP-2 Skin Test Reagent

Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution

Sponsors & Collaborators

  • Albert B. Sabin Vaccine Institute

    lead OTHER

Principal Investigators

  • Jeffrey Bethony, PhD · Albert B. Sabin Vaccine Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-01-31
Completion
2012-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939198 on ClinicalTrials.gov